ClinicalTrials.gg
CompletedNCT01489553Updated Oct 22, 2013

Egg Oral Immunotherapy

An observational study in Egg Hypersensitivity, sponsored by Children's Hospital of Philadelphia. Completed. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2013-10-22.

Sponsored by Children's Hospital of Philadelphia · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
9
Ages
6 Years to 17 Years
Sex
All
01

Study summary

For patients with Immunoglobulin E (IgE)-mediated food allergy, the current management includes identification of the causative food and avoidance. Egg allergy is among the most common causes of IgE-mediated food allergy in children, affecting approximately 1.6% of children (its prevalence is higher in children with atopic dermatitis or other food allergies). Given the prevalence of egg and the difficulty to avoid it in the diet, we aim to investigate the safety and efficacy of baked egg oral immunotherapy.

Read the detailed description

The primary objective is to study the efficacy of baked egg oral immunotherapy. The secondary objectives are to determine the safety of allergen-specific immunotherapy for egg allergy through ingestion of baked egg products and whether it will ultimately lead to a desensitized state for native egg. We will also examine if quality of life is improved by expansion of diets.

Subjects aged six to 17 years with a history of egg protein allergy will be recruited from The Children's Hospital of Philadelphia (CHOP) Allergy practice (main campus and satellite locations).

Prior to and after the desensitization to baked egg, we will conduct double blind placebo-controlled food challenges to native egg protein. During the desensitization phase, we will give increasing doses of baked egg (meringue cookie or equivalent) on a weekly basis, as tolerated.

The primary endpoint of the study includes the percentage of subjects who can successfully complete the food challenge to native egg once they have completed the desensitization protocol to baked egg. Secondary outcome measures include egg-specific IgE, quality of life before and after desensitization, and egg skin prick test size.

02

Conditions studied

  • Egg Hypersensitivity

Browse trials for

Keywords

  • Egg hypersensitivity
  • egg allergy
  • egg protein allergy
03

In context

Egg Hypersensitivity

38 studies on the registry are indexed under Egg Hypersensitivity; 9 are open to participants now.

Browse Egg Hypersensitivity studies →

Lead sponsor

Children's Hospital of Philadelphia is the lead sponsor of 489 studies on the registry; 90 are open to participants now.

Of its 28 completed or terminated interventional studies of FDA-regulated products, 22 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

outpatient Allergy patients followed at The Children's Hospital of Philadelphia

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must satisfy all inclusion criteria:

  1. Subjects must be age six to 17 years and have a history of egg allergy. Subjects shall maintain strict avoidance of consumption of all egg protein containing foods.
  2. Subjects will have a history (within the past six months) of a positive skin prick test to egg extract or an immunocap IgE level greater than 0.35 kU/L, and a positive allergic reaction history to egg within the past 12 months.

    a. Subjects will be accepted to the study if they have had a positive food challenge conducted at CHOP in the three months prior to the start of the study.

  3. Subjects must be in good health, as determined by medical history and physical examination performed by a study physician.
  4. Females of must be using an effective method of , including abstinence, and agree to continue to practice an acceptable method of contraception for the duration of their participation in the study.

    If a positive pregnancy test was obtained during the study, the subject will be asked to withdraw from the study.

  5. of parent or legal guardian is required.

Exclusion criteria

Exclusion Criteria:

Subjects will be excluded from the study if they meet any one of the following criteria:

  1. Ability to tolerate baked goods containing egg or the ability to tolerate a serving size of egg (6.3 grams of egg protein.)
  2. Pregnancy.
  3. A history of food protein induced enterocolitis syndrome to egg.
  4. A history of eosinophilic esophagitis, where egg has been identified as a causative food.
  5. A history of anaphylaxis requiring overnight hospitalization.
  6. A history of intubation related to asthma and/or a history of an intensive care unit admission for asthma management.
  7. A current diagnosis of severe persistent asthma [ (forced expiratory volume in 1 second) \< 60% of predicted, as defined by NHLBI (National Heart, Lung, and Blood Institute) guidelines, despite current therapy].
  8. A current diagnosis of severe atopic dermatitis.
  9. A serious chronic medical condition, including neurologic, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, or metabolic disease.
  10. Use of oral or injection within one month of protocol initial visit.

    a. Should it become necessary for a subject to be on systemic corticosteroids while on the study, the subject will either be withdrawn from the study or the use of corticosteroids during the study will be taken into account during data analysis. The PI and lead investigators will make that decision based on the individual case.

  11. An acute illness within one week prior to the first dose of oral immunotherapy.
  12. Use of antihistamines within three days prior to Double blind placebo-controlled food challenge (DBPCFC).
  13. Use of chronic immunomodulatory therapy.
  14. Participation in another experimental therapy study.
  15. Participation in a study for the treatment of food allergy in the past 12 months.
  16. Inability to discontinue antihistamines for skin testing and food challenges.
  17. A positive pregnancy test.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
9 participants (actual)
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. Percentage of children completing desensitization

    Evaluate proportion of subjects who successfully complete the food challenge to native egg upon completion of the desensitization protocol to baked egg.

    Time frame: Baseline & 12 months

Secondary outcomes

  1. Change in Egg specific IgE values at the beginning and end of desensitization

    Specific IgE values will be compared for egg at the beginning and the end of the desensitization protocol.

    Time frame: Baseline & 12 months

  2. Change in quality of life variables

    Comparison of quality of life before and after desensitization through the completion of a voluntary and confidential survey.

    Time frame: Baseline & 12 months

  3. Number of participants with adverse events

    Determine the safety of allergen-specific immunotherapy for egg allergy through ingestion of baked egg products and whether it will ultimately lead to a desensitized state for native egg.

    Time frame: Baseline & 12 months

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 22, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01489553
Responsible party
Sponsor
First posted
Dec 9, 2011
Start date
Jan 2012
Primary completion
Sep 2013
Completion
Oct 2013
Last update
Oct 22, 2013

Study contacts

Jonathan M. Spergel, MD, PhD
principal investigator · Children's Hospital of Philadelphia
Rushani W. Saltzman, MD
study director · Children's Hospital of Philadelphia

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion